1. This case-control study found that in patients with atrial fibrillation concomitant Serotonin Reuptake Inhibitor (SSRI) and Oral Anticoagulants (OAC) was associated with an increased risk of major bleeding compared with OAC use alone. 2. This increased risk was highest in the first 30 days of continuous, concomitant use. Evidence Rating Level: 2 (Good) Antidepressants,
Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding 1. This case-control study found that in patients with atrial fibrillation concomitant Serotonin Reuptake Inhibitor (SSRI) and Oral Anticoagulants (OAC) was associated with an increased risk of major bleeding compared with OAC use alone. 2. This increased risk was highest
Kesin Pharma Announces FDA Approval and U S Availability of LIKMEZ™ (metronidazole) Oral Suspension streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Kesin Pharma Announces FDA Approval and U S Availability of LIKMEZ™ (metronidazole) Oral Suspension eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.